ResMed Leverages Margin Gains and New Fabric Masks to Power 11% Revenue Surge Amid Leadership Turnover

ResMed (RMD) opened its fiscal 2026 Q3 earnings call with a clear message: “We delivered another set of strong results, including 11% growth in headline revenue, or 8% growth on a constant‑currency basis.” The 11% lift—driven by a $1.43 billion top line—was underpinned by double‑digit gains in its mask and accessories portfolio, which grew 12% year‑over‑year, and a 6% rise in device sales.

The company’s geographic spread also broadened, with the United States, Canada and Latin America posting 9% revenue growth and Europe, Asia and the rest of the world adding 7% on a constant‑currency basis.

Margin expansion was the centerpiece of management’s commentary. Gross margin climbed to 62.8%, a 290‑basis‑point improvement versus the prior year and a 50‑basis‑point sequential gain. “Our gross margin expansion in the quarter was strong: 290 basis points year over year and 50 basis points sequentially,” said CEO Michael J.

Farrell, emphasizing that the improvement stemmed from “component cost improvements, manufacturing and logistics efficiencies, and a small positive impact from product mix and foreign currency movements.” The operating margin followed suit, rising to 36.7% from 34.4% a year earlier, delivering an 18% jump in non‑GAAP operating income.

Free cash flow surged to $520 million, representing more than 100% conversion of operating cash flow, and the balance sheet remained robust with $1.7 billion in cash, $664 million of gross debt and $996 million of net cash. The company returned $262 million to shareholders—$87 million in a quarterly dividend of $0.60 per share and $175 million in share repurchases—while pledging to sustain “significant capital deployment” into R&D and sales‑and‑marketing initiatives.

The earnings narrative was punctuated by two strategic developments. First, the board announced the retirement of long‑time CFO Brett Sandercock after 26 years, and the appointment of Aaron Blumer, formerly CFO of Exact Sciences, as his successor. “Aaron brings more than 17 years of global financial leadership… his international perspective will be invaluable as we continue to execute on our global 2030 strategy,” Farrell said.

Second, ResMed disclosed a definitive agreement to acquire Noctrix Health for $340 million, targeting a niche but sizable restless‑leg‑syndrome (RLS) market that affects roughly 7% of adults worldwide. The Noctrix NIDRA device, a non‑invasive nerve‑stimulation therapy, “has higher gross margins than ResMed and is growing faster than our own business,” Farrell noted. The acquisition, slated to close around June 1, 2026, will be folded into the Americas devices segment, with an expected modest EPS dilution of $0.02 in Q4.

Product innovation also took center stage. The rollout of fabric‑based masks—AirTouch N30i, F30i Comfort and F30i Clear—has begun to shift the competitive landscape. Real‑world data showed the AirTouch N30i delivering a 6% lift in 90‑day compliance versus its silicone counterpart, a gain that translates into “600 basis points of extra compliance” in lifetime value, according to Farrell.

“Those 600 basis points of extra compliance will mean a lot as this technology expands,” he added, highlighting the masks’ role in bolstering adherence, a key revenue driver in the CPAP market.

ResMed’s digital ecosystem also advanced, with the AirSense 11 platform now live in Latin America and China, and a localized Chinese digital experience that integrates WeChat for personalized patient engagement. The company’s continuing medical education (CME) programs reached 80,000 completions by 45,000 clinicians, with 78% indicating an intent to alter practice patterns—a metric that management believes will fuel future device and mask uptake.

Analysts pressed management on several fronts. Morgan Stanley’s David Bailey asked about component cost trends and freight pressures. Farrell responded that while “fuel costs and emerging component cost pressures” exist, the company’s supply‑chain pipeline—standardization, longer‑term vendor contracts and freight optimization—should sustain margin accretion through 2030.

Jarden’s analyst probed the Noctrix deal, receiving confirmation that higher margins and growth rates are expected, but that additional SG&A and R&D spend will be required to scale the product. Barrenjoey’s analyst sought color on Europe/Asia growth; Farrell cited “fabric mask adoption” and “omnichannel approaches” in China, Korea, Australia and New Zealand as primary levers.

A recurring theme in the Q&A was the intersection of GLP‑1 weight‑loss drugs and PAP therapy. Farrell cited internal analyses of 1.7 million and 2.1 million patient records, showing that patients who start GLP‑1 therapy are 5–6% more likely to resupply PAP equipment over two‑ to three‑year horizons.

“The data are in sync. We believe GLP‑1s are truly a megatrend, and a once‑in‑a‑generation demand‑gen opportunity for ResMed,” he asserted, positioning the company to capture a broader wave of patients entering the sleep‑health funnel.

Looking ahead, ResMed reaffirmed its long‑term growth targets. Management reiterated guidance for “high single‑digit revenue growth” through 2030, with operating margins expected to stay in the low‑60% range. The company expects the Noctrix acquisition to be accretive to earnings in the mid‑term, and it will continue to invest in digital health, AI‑enabled algorithms and next‑generation masks to sustain its “operational excellence” narrative.

The market reacted modestly. ResMed shares edged up 0.89% to $213.81 in after‑hours trading, still trailing a 2.60% decline over the week and a 11.23% drop year‑to‑date, and remaining 27.2% below the 52‑week high. The modest price appreciation reflects investor confidence in the margin trajectory and product pipeline, tempered by the broader macro‑environment and the near‑term earnings impact of the Noctrix integration.